Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Lexicon Pharmaceuticals Inc

Healthcare US LXRX

1.96USD
0.04(2.08%)

Last update at 2026-06-15T20:00:00Z

Day Range

1.921.98
LowHigh

52 Week Range

0.923.73
LowHigh

Fundamentals

  • Previous Close 1.92
  • Market Cap610.92M
  • Volume2080007
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-185.35501M
  • Revenue TTM2.31M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM -52.67700M
  • Diluted EPS TTM-0.87

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -101.94400M -87.75800M -58.57400M 124.12M -120.54800M
Minority interest - - - - -
Net income -103.12800M -88.26800M -70.18400M 130.13M -120.54800M
Selling general administrative 48.08M 32.34M 0.05M 56.84M 63.75M
Selling and marketing expenses - - - - -
Gross profit 0.14M 0.30M 22.07M 318.84M 60.72M
Reconciled depreciation 0.43M 0.29M 2.93M 3.65M 3.68M
Ebit -100.76000M -87.09000M -178.78500M 141.44M -103.45400M
Ebitda -99.16400M -86.95600M -176.01800M 173.43M -99.77100M
Depreciation and amortization 1.60M 0.13M 2.77M 31.99M 3.68M
Non operating income net other 1.60M 0.13M 3.77M 3.35M 3.51M
Operating income -100.76000M -87.09000M -178.78500M 141.44M -103.27900M
Other operating expenses 100.90M 87.39M 202.78M 151.99M 166.49M
Interest expense 2.78M 0.80M 14.54M 20.68M 20.78M
Tax provision - 0.00000M 0.00000M -6.01400M 0.00000M
Interest income 1.60M 0.13M 2.77M 3.35M 3.51M
Net interest income -1.18400M -0.66800M -11.77700M -17.32600M -17.26900M
Extraordinary items - - - - -
Non recurring - - 1.60M -28.63800M -
Other items - - - - -
Income tax expense 1.18M 0.51M 11.61M -6.01400M 3.51M
Total revenue 0.14M 0.30M 24.00M 322.07M 63.21M
Total operating expenses 100.90M 87.39M 200.85M 148.76M 164.00M
Cost of revenue 0.00000M 0.00000M 1.93M 3.23M 2.49M
Total other income expense net -1.18400M -0.66800M 120.21M -17.32600M -17.26900M
Discontinued operations - - - - -
Net income from continuing ops -101.94400M -87.75800M -58.57400M 130.13M -120.54800M
Net income applicable to common shares -101.94400M -87.75800M -58.57400M 130.13M -120.54800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 229.43M 194.30M 136.91M 203.79M 417.71M
Intangible assets - - - - 19.72M
Earning assets - - - - -
Other current assets 5.13M 2.48M 2.16M 5.05M 5.32M
Total liab 136.32M 77.17M 23.31M 47.42M 300.61M
Total stockholder equity 93.11M -1589.72000M -1487.77600M 156.37M -1341.44400M
Deferred long term liab - - - - -
Other current liab 15.87M 11.49M 11.88M 0.98M 42.15M
Common stock 0.24M 0.19M 0.15M 0.14M 0.11M
Capital stock 0.24M 0.19M 0.15M 0.14M 0.11M
Retained earnings -1766.83900M -1589.72000M -1487.77600M -1400.01800M -1341.44400M
Other liab - - 23.31M 35.77M 55.43M
Good will 44.54M 44.54M 44.54M 44.54M 44.54M
Other assets - - 136.91M 1.23M -0.04500M
Cash 22.46M 46.34M 64.06M 126.26M 36.11M
Cash and equivalents - - - - -
Total current liabilities 31.55M 23.17M 22.12M 46.81M 65.34M
Current deferred revenue - - - 28.16M -
Net debt 83.60M 8.95M -61.78600M -113.45300M 210.17M
Short term debt 1.29M 1.29M 1.09M 12.20M 11.01M
Short long term debt - - - 11.65M 11.01M
Short long term debt total 106.06M 55.29M 2.28M 12.81M 246.28M
Other stockholder equity 1859.67M 0.24M -0.14000M 1556.25M -0.19000M
Property plant equipment - 2.07M 1.18M 0.29M 14.05M
Total current assets 176.55M 140.87M 88.92M 157.72M 337.75M
Long term investments - - - - -
Net tangible assets - 72.58M 69.05M 111.83M 52.84M
Short term investments 147.56M 92.01M 22.68M 26.01M 235.55M
Net receivables 1.01M 0.03M 0.01M 0.40M 56.53M
Long term debt 99.51M 48.58M - - 234.17M
Inventory 0.38M - - 0.00000M 4.24M
Accounts payable 14.39M 10.39M 9.15M 5.47M 12.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.03M -0.42800M -0.01000M -0.00600M 0.08M
Additional paid in capital - - - - -
Common stock total equity - 0.19M 0.15M 0.14M 0.11M
Preferred stock total equity - - - - -
Retained earnings total equity - -1589.72000M -1487.77600M -1400.01800M -1341.44400M
Treasury stock - -2.06100M -7.51800M -4.84300M -3.81700M
Accumulated amortization - - - - -
Non currrent assets other 0.83M 6.82M 2.27M 1.23M 1.66M
Deferred long term asset charges - - - - -
Non current assets total 52.88M 53.43M 47.99M 46.07M 79.96M
Capital lease obligations 6.56M 6.71M 2.28M 1.16M 1.10M
Long term debt total - - - - 234.17M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -69.75200M 3.33M 209.44M -155.78500M 169.67M
Change to liabilities 0.08M -14.15800M -20.96900M -5.89300M -42.85300M
Total cashflows from investing activities -71.07800M 2.11M 380.76M -155.85500M 169.58M
Net borrowings 48.87M -11.70000M -216.58000M -1.28500M -2.00400M
Total cash from financing activities 142.21M 22.71M -147.63600M -2.22600M -2.24400M
Change to operating activities 0.34M 3.55M -1.52400M -2.22300M 1.91M
Net income -101.94400M -87.75800M -58.57400M 130.13M -120.54800M
Change in cash -17.72000M -62.19800M 90.15M -44.27400M 18.73M
Begin period cash flow 64.06M 126.26M 36.11M 80.39M 61.66M
End period cash flow 46.34M 64.06M 126.26M 36.11M 80.39M
Total cash from operating activities -88.85100M -87.01700M -142.96900M 113.81M -148.60700M
Issuance of capital stock 94.20M 37.08M 69.97M 0.00000M 0.73M
Depreciation 0.43M 0.29M 2.93M 3.65M 3.68M
Other cashflows from investing activities - - 171.40M -155.78500M 169.67M
Dividends paid - -11.70000M -216.58000M - -
Change to inventory 0.00000M 0.00000M 0.34M 0.44M -2.73200M
Change to account receivables -0.01400M 0.38M 53.23M -50.60800M -1.09900M
Sale purchase of stock -0.86400M -2.67500M -1.02600M -0.94100M -0.97200M
Other cashflows from financing activities 97.74M 11.70M 216.58M -155.85500M 12.53M
Change to netincome 11.52M 10.63M 12.57M 8.20M 11.70M
Capital expenditures 1.33M 1.22M 0.09M 0.07M 0.10M
Change receivables -0.01400M 0.38M 53.23M -50.60800M -1.09900M
Cash flows other operating 0.34M 3.55M -1.52400M -2.22300M 1.91M
Exchange rate changes - - - - -
Cash and cash equivalents changes -17.72000M -62.19800M 90.15M -44.27400M 18.73M
Change in working capital 0.40M -10.23100M 31.08M -58.28700M -44.77400M
Stock based compensation 11.52M 10.58M 13.27M 14.22M 11.70M
Other non cash items 0.74M 0.05M -131.57200M 30.10M 1.34M
Free cash flow -90.17700M -88.23800M -143.05600M 113.74M -148.70200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LXRX
Lexicon Pharmaceuticals Inc		 0.04 2.08% 1.96 - - 402.90 5.21 349.77 -2.5763
NVO
Novo Nordisk A/S		 0.04 0.09% 43.92 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.40 0.91% 44.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.54 1.24% 450.46 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.84 0.46% 614.98 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals Inc

2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381

Key Executives

Name Title Year Born
Mr. Lonnel Coats CEO & Director 1965
Mr. Jeffrey L. Wade J.D. Pres & CFO 1965
Mr. Brian T. Crum Sr. VP, Gen. Counsel & Sec. 1973
Dr. Alan J. Main Ph.D. Exec. VP of Innovation & Chemical Sciences 1954
Dr. Craig B. Granowitz M.D., Ph.D. Sr. VP & Chief Medical Officer 1965
Dr. Robert J. Lefkowitz M.D. Consultant & Independent Director 1944
Ms. Kristen L. Alexander VP of Fin. & Accounting 1968
Mike Kelly Investor Relations Officer NA
Chas Schultz Exec. Director of Corp. Communications & Patient Advocacy NA
Ms. Wendy E. McDermott VP of HR 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.